Additionally, SCFAs reduce peroxisome proliferator-activated receptor gamma (PPAR-γ) expression, thereby enhancing oxidative metabolism in the liver and adipose tissue, which in turn decreases fat accumulation, mitigates hepatic steatosis, and improves insulin sensitivity [69]. This evidence concerns the gene PPARG and fatty liver disease.